Collegium Q2 revenue $123.5M record, raises FY Adj EBITDA guidance to $245-255M

COLLEGIUM PHARMACEUTICAL, INC

2022-Q2 EPS reported -$0.54 revenue$207,300,000

Q2 net product revenue $123.5M (record), up from $82.9M YoY.
GAAP net loss $5.2M ($0.15 loss per share) vs $72.8M income in prior year (included tax benefit).
Adjusted EBITDA $71.2M, up from $40.1M YoY; full-year Adj EBITDA guidance raised to $245-255M.
BDSI integration complete; on track to exceed targeted run-rate synergies of at least $75M.
Opioid lawsuits resolved via master settlement agreement covering 27 pending cases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.